Pharmacogenomic markers of glucocorticoid response in the initial phase of remission induction therapy in childhood acute lymphoblastic leukemia
- Gasic Vladimir
- Zukic Branka
- Stankovic Biljana
- Janic Dragana
- Dokmanovic Lidija
- Lazic Jelena
- Krstovski Nada
- Dolzan Vita
- Jazbec Janez
- Pavlovic Sonja
- Kotur Nikola
Publication date
September 2018
DOI Publisher
Walter de Gruyter GmbH ISSN
1581-3207 Journal
Radiology and OncologyAbstract
Response to glucocorticoid (GC) monotherapy in the initial phase of remission induction treatment in childhood acute lymphoblastic leukemia (ALL) represents important biomarker of prognosis and outcome. We aimed to study variants in several pharmacogenes (NR3C1, GSTs and ABCB1) that could contribute to improvement of GC response through personalization of GC therapy
Add to ORKG